EGFR and non-small cell lung carcinoma: Despite the successes of third-generation TKIs in overcoming T790M mutations, recent research from Yonsei University’s Department of Medicine in Seoul, South Korea, has revealed that all three generations of TKIs have been ineffective against NSCLC patients harboring the C797S mutation in the EGFR [69].